GLAXF.US GSK plc

Healthcare Pharmaceuticals USA Stocks
25.23 USD
Close of Nov 14, 2026
21.71 30.41
Market cap
USD 101B
P/E
17.6x
P/B
4.04x
ROE
26.1%
Dividend yield
3.57%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GLAXF.US undervalued?

Graham number
Price25.23
Graham value14.17
Premium78.0%

GLAXF.US trades 78.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GSK plc fundamental analysis

No fundamental analysis for GSK plc yet.

GSK plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, …

Full company profile